Global Addison’s Disease Drugs Market, By Drug Class (Glucocorticoid, Mineralocorticoid, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Addison’s Disease Drugs Market Analysis and Size
The global addison’s disease drugs market is expected to witness significant growth during the forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market. The growth of addison’s disease drugs market enhanced by the growing cases of addison’s disease and rise in research and development activities conducted by many pharmaceuticals’ companies. Further R&D is launching advanced treatments wherein adrenocortical stem cells will be mixed with immunomodulatory treatment, resulting in immune system modification.
Data Bridge Market Research analyses a growth rate in the global addison’s disease drugs market in the forecast period 2022-2029. The expected CAGR of global addison’s disease drugs market is tend to be around 10.50% in the mentioned forecast period. The market was valued at USD 500 million in 2021, and it would grow upto USD 1111.39 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Addison’s disease drugs, also called hypocortisolism or primary adrenal insufficiency, is a potentially life-threatening condition in which the body does not produce enough cortisol or aldosterone. The signs and symptoms of addison’s disease are fatigue, nausea, darkening of the skin and dizziness. Its treatment involves medication to treat unbalanced levels of hormone in the body. These medications involve hydrocortisone, prednisone & methylprednisolone, and fludrocortisone acetate. All these factors tend to increase the market growth.
Addison’s Disease Drugs Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
By Drug Class (Glucocorticoid, Mineralocorticoid, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Bristol-Myers Squibb Company (U.S.), Merck & Co., Inc (U.S.), Novartis AG (Switzerland), Pfizer Inc (U.S.), Takeda Pharmaceutical Company (Japan), Bio-Techne (U.S.), GlaxoSmithKline plc (U.S.), Lupin (India), Abbott (U.S.), Amgen Inc (U.S.), Bayer AG (Germany), Eli Lilly and Company (U.S.)
Global Addison’s Disease Drugs Market Dynamics
- Need For Long-Term Treatment
Addison's disease requires long term treatment with steroid replacement therapy. Glucocorticoid and mineralocorticoid replacement therapies are currently the most commonly used treatments for addison's disease. In addition, hydrocortisone is one of the most preferred drugs in the glucocorticoid class due to its short half-life and ability to absorb into the bloodstream rapidly. In addition, long-acting glucocorticoids such as dexamethasone and prednisone are beneficial for once-daily dosing schedules. This boost the market growth.
- Increased Healthcare Infrastructure and Government Initiatives
The existence of an established health care infrastructure, government initiatives to implement addison's disease treatment, and constantly improving reimbursement scenarios are expected to drive the market growth. Europe was the second largest addison's disease treatment market due to improved health care practices and high demand for health care in the region.
- Rising Incidence of Addison’s Disease
Addison's disease is a rare adrenal gland hormonal disorder affecting less than 1 million people worldwide. The growth of the Addison disease drug market can be attributed to a variety of factors such as raising awareness of the disease and the diagnoses available for it, prescribing medicines, names of special medicines, and various reimbursement policies.
- Increasing Demand for Diagnostic Tests
Blood tests are the main source of information for diagnosing Addison's disease. This is because blood tests correctly show the levels of sodium, potassium, cortisol, and adrenocorticotropic hormone (ACTH), which are involved in producing adrenal hormones. Next is the ACTH stimulation test. ACTH signals the adrenal glands to produce hormones, and this test confirms the absence of secondary adrenal insufficiency. Thus, all these tests increase the market opportunities.
- Lack of skilled professionals
The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global addison’s disease drugs market over a forecast period.
- High Cost
The huge expenditure associated with addison’s treatment medications surely hamper the market growth.
This global addison’s disease drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global addison’s disease drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Addison’s Disease Drugs Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.
In the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge future growth due to the demand for vaccine and treatment drugs for COVID-19. Thus, this will significantly impact the addison’s disease drugs market.
Global Addison’s Disease Drugs Market Scope
The global addison’s disease drugs market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Addison’s Disease Drugs Market Regional Analysis/Insights
The global addison’s disease drugs market is analysed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global addison’s disease drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
America is dominating the market in the forecast period due to the large number of healthcare services and demand of products for huge storage and repository.
Asia-Pacific is considered the most lucrative period due to the region's increasing number of biobanks and hospitals.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Addison’s Disease Drugs Market Share Analysis
The global addison’s disease drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global addison’s disease drugs market
Key players operating in the global addison’s disease drugs market include:
- Bristol-Myers Squibb Company (U.S.)
- Merck & Co., Inc (U.S.)
- Novartis AG (Switzerland)
- Pfizer Inc (U.S.)
- Takeda Pharmaceutical Company (Japan)
- Bio-Techne (U.S.)
- GlaxoSmithKline plc (U.S.)
- Lupin (India)
- Abbott (U.S.)
- Amgen Inc (U.S.)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
Research Methodology: Global Addison’s Disease Drugs Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.